Brain cancer drug trial halted early – no results yet

NCT ID NCT01068782

First seen Mar 12, 2026 · Last updated May 14, 2026 · Updated 9 times

Summary

This study tested the drug XL184 in 19 people whose grade IV brain tumors (a serious type of cancer) had come back after initial treatment. The goal was to see if the drug could shrink tumors or slow their growth. However, the company stopped the study early for business reasons, so we don't know if XL184 worked. The main information collected was about side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTROCYTIC TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Study site

    Birmingham, Alabama, 35294, United States

  • Study site

    Encinitas, California, 92024, United States

  • Study site

    Pleasant Hill, California, 94523, United States

  • Study site

    Chicago, Illinois, 60611, United States

  • Study site

    Chicago, Illinois, 60637, United States

  • Study site

    Boston, Massachusetts, 02115, United States

  • Study site

    Detroit, Michigan, 48202, United States

  • Study site

    Minneapolis, Minnesota, 55407, United States

  • Study site

    Amherst, New York, 14226, United States

  • Study site

    Rochester, New York, 14642, United States

  • Study site

    Cleveland, Ohio, 44195, United States

  • Study site

    Hershey, Pennsylvania, 17033, United States

  • Study site

    Dallas, Texas, 75246, United States

  • Study site

    Dallas, Texas, 75426, United States

  • Study site

    San Antonio, Texas, 78229, United States

  • Study site

    Charlottesville, Virginia, 22908, United States

  • Study site

    Seattle, Washington, 98122, United States

  • Study site

    Calgary, Alberta, Canada

  • Study site

    Montreal, Quebec, Canada

Conditions

Explore the condition pages connected to this study.